iPredict: automated AI for early detection and prediction of late age-related macular degeneration

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational pivotal trial tests iPredict, an automated AI system that analyzes non-dilated fundus photos taken in primary care and general ophthalmology settings. Images will be captured using an FDA-approved DRSPlus fundus camera and uploaded securely to the cloud for automated analysis. The AI outputs will be validated prospectively against optical coherence tomography (OCT) scans and color fundus images to determine diagnostic and predictive accuracy for late AMD. Individuals already diagnosed with AMD or receiving retinal treatment are excluded, and prior comparisons versus ophthalmologist reads have shown sufficient accuracy to justify this validation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects will be recruited if willing and able to comply with clinic visit and study-related procedures, and provide signed informed consent

Exclusion Criteria:

* Already diagnosed with AMD, unable to provide informed consent and currently under treatment of retinal disease.

Where it's running

• iHealthScreen Inc.
  Richmond Hill, New York, United States Recruiting

Study contacts

• Principal investigator: Alauddin Bhuiyan, PhD — iHealthScreen Inc
• Study coordinator: Alauddin Bhuiyan
• Email: bhuiyan@ihealthscreen.org
• Phone: 718-926-9000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Enhanced vision and imaging tests to enable treatments for early and intermediate AMD

  We will see if a fundus-tracked dark adaptometry test can reliably detect and track vision changes in people with early or intermediate AMD and in healthy volunteers.

  Recruiting University Hospital, Bonn · Bonn · NCT07515521

• Finding protein biomarkers for AMD, diabetic retinopathy, and retinal detachment

  This project will test whether proteins found in blood and eye fluids can help diagnose or predict outcomes for adults with AMD, diabetic retinopathy, or retinal detachment.

  Recruiting Fondazione G.B. Bietti, IRCCS · Roma, Italy · NCT07500324

• Early response to Eylea 8 mg in neovascular (wet) age-related macular degeneration

  This observational project will try Eylea (aflibercept) 8 mg eye injections to see how retinal fluid and vision change over the first two months in people with active neovascular AMD.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT07434713

• SING IMT implant for pseudophakic patients with advanced AMD

  This study will test whether the SING IMT™ implant, placed either on top of or replacing an existing intraocular lens, can improve central vision in people with advanced AMD who already have IOLs.

  Recruiting at 12 sites VisionCare, Inc. · Marseille and 11 other locations · NCT07164378

• AI-assisted eye screening for diabetic retinopathy and age-related macular degeneration in outpatient clinics

  This project will test whether the VeriSee AI software helps doctors find diabetic eye disease and macular degeneration earlier in adults with diabetes or people aged 50 and older.

  Recruiting National Taiwan University Hospital · Taipei · NCT07069647

• VeriSee AI for screening macular degeneration and diabetic retinopathy

  This trial will test whether the VeriSee AI software can help doctors screen for age-related macular degeneration in adults 50+ and diabetic retinopathy in diabetic adults 20+.

  Recruiting National Taiwan University Hospital · Taipei, Taiwan · NCT06843499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.